MARGENZA

PeakmAb

margetuximab-cmkb

MacroGenics
BLAINJECTIONINJECTABLE
Approved
Dec 2020
Lifecycle
Peak
Competitive Pressure
30/100

Mechanism of Action

HER2/Neu/cerbB2 Antagonists

Pharmacologic Class:

HER2/neu Receptor Antagonist

Company
M
MacroGenics
MD - Rockville
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers